{"id":33833,"date":"2023-09-26T14:07:10","date_gmt":"2023-09-26T12:07:10","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=33833"},"modified":"2023-09-21T14:16:48","modified_gmt":"2023-09-21T12:16:48","slug":"atypische-indikationen-fuer-antithrombotika-bei-koronarer-herzkrankheit-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2023\/atypische-indikationen-fuer-antithrombotika-bei-koronarer-herzkrankheit-cme","title":{"rendered":"\u201eAtypische\u201c Indikationen f\u00fcr Antithrombotika bei Koronarer Herzkrankheit [CME]"},"content":{"rendered":"<p>Antithrombotisch wirksame Medikamente geh\u00f6ren zu den am meisten verschriebenen Arzneimitteln. H\u00e4ufige Indikationen f\u00fcr eine antithrombotische Langzeit-\/Dauertherapie sind KHK und Vorhofflimmern (Vofli). Folgende Therapiekonzepte sind als Standard etabliert: bei KHK: \u2013\u00a0stabil: Antithrombozyt\u00e4re Monotherapie mit ASS in der Sekund\u00e4rpr\u00e4vention; bei selektierten Patienten auch in der Prim\u00e4rpr\u00e4vention; \u2013\u00a0nach elektiver oder akuter perkutaner Koronarintervention (PCI) oder akutem Koronarsyndrom (ACS): [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antithrombotisch wirksame Medikamente geh\u00f6ren zu den am meisten verschriebenen Arzneimitteln. H\u00e4ufige Indikationen f\u00fcr eine antithrombotische Langzeit-\/Dauertherapie sind KHK und Vorhofflimmern (Vofli). Folgende Therapiekonzepte sind als Standard etabliert: bei KHK: \u2013\u00a0stabil: Antithrombozyt\u00e4re Monotherapie mit ASS in der Sekund\u00e4rpr\u00e4vention; bei selektierten Patienten auch in der Prim\u00e4rpr\u00e4vention; \u2013\u00a0nach elektiver oder akuter perkutaner Koronarintervention (PCI) oder akutem Koronarsyndrom (ACS): [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3270,684,495,137,1322,1272,76,73,2305,1314,1312,2068,71,85,86,498,65,1328,1327,83,84,87,1033,79,2304,2005],"class_list":["post-33833","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalizylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-antikoagulanzien","tag-apixaban","tag-arteriosklerose","tag-azetylsalizylsaeure","tag-clopidogrel","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-herzinfarkt","tag-koronarangiografie","tag-koronarangiographie","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-rivaroxaban","tag-ticagrelor"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/33833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=33833"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/33833\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=33833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=33833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=33833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}